Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Controversies in early stage triple negative breast cancer

Role of biomarkers / ctDNA monitoring in therapy decisions

Date

23 Oct 2023

Session

Controversies in early stage triple negative breast cancer

Topics

Clinical Research;  Cancer Biology;  Tumour Immunology;  Translational Research;  Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Aleix Prat

Authors

A. Prat

Author affiliations

  • Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Discussion

Presenter: All Speakers

Session: Controversies in early stage triple negative breast cancer

Resources:

Slides

Webcast

Conclusions and perspectives 

Presenter: Rebecca Dent

Session: Controversies in early stage triple negative breast cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.